The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almo
Grifols is gearing up to file for approval of a drug for rare bleeding disorder acquired fibrinogen deficiency (AFD) that could provide a more reliable and easier treatmen
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl